Last reviewed · How we verify

Protalix — Portfolio Competitive Intelligence Brief

Protalix pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
PRX-102 (pegunigalsidase alfa) PRX-102 (pegunigalsidase alfa) phase 3 Enzyme replacement therapy (ERT) α-galactosidase A (GLA) Rare genetic disease / Lysosomal storage disorder

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AM-Pharma · 1 shared drug class
  2. AO GENERIUM · 1 shared drug class
  3. Fondation Ophtalmologique Adolphe de Rothschild · 1 shared drug class
  4. Genzyme, a Sanofi Company · 1 shared drug class
  5. ISU Abxis Co., Ltd. · 1 shared drug class
  6. The Hospital for Sick Children · 1 shared drug class
  7. University Hospital, Strasbourg, France · 1 shared drug class
  8. University of Jena · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Protalix:

Cite this brief

Drug Landscape (2026). Protalix — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/protalix. Accessed 2026-05-13.

Related